Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of

June 02, 2025 11:09 PM IST | By EODHD
 Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of
Image source: Kalkine Media
Sanofi (NASDAQ:SNY) is making another bold move to cement its position in immunology, agreeing to acquire Blueprint Medicines (NASDAQ:BPMC) for $129 a share in cashplus up to $6 in milestone payments tied to future success of its next-gen drug candidate BLU-808. That pegs the total deal at around $9.5 billion, a 40% premium over Blueprint's 30-day average. The prize? Ayvakit, the only approved treatment for systemic mastocytosis (SM)a rare and debilitating immune disorderas well as a pipeline that could unlock broader inflammatory markets. Warning! GuruFocus has detected 1 Warning Sign with SNY. Ayvakit is no science project. The drug pulled in $479 million last year and nearly $150 million in Q1 2025, up more than 60% year-over-year. And this isn't a one-hit wonder. Sanofi's also picking up elenestinib (currently in Phase 2/3) and BLU-808an oral KIT inhibitor that could have applications well beyond SM. The deal could plug directly into Sanofi's immunology machine, which already includes Dupixent, and give it deeper reach among allergists and immunologists. CEO Paul Hudson called the deal a strategic step forward and suggested more acquisitions could be on the horizon. If all goes to plan, the transaction closes by Q3 2025. It won't move the needle on Sanofi's 2025 financials, but it could begin lifting margins and earnings starting in 2026. Sanofi's paying cash and tapping some fresh debt, but the tender offer isn't contingent on financing. For Blueprint, it's a scale-up opportunityand a potential fast-pass to bring its early-stage science to more patients globally. The bet here is simple: Sanofi sees rare immunology not just as a niche, but as a high-margin, high-loyalty growth engineand it's not done building. This article first appeared on GuruFocus. View Comments

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.